Back to search
FDAFDA · Food and drugs·Recall number D-0952-2016

Ceftriaxone for Injection USP, 500 mg, Single Use Vial, packaged in a) 1-count Vials per box (NDC 68180-622-01), and b) 10-count Vials per box (NDC 68180-622-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., 111 South Calvert Street, Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Mandideep 462 046 INDIA.

Published June 8, 2016 · Recall initiated: March 11, 2016

Summary

FDA records drug Class III recall D-0952-2016, published June 8, 2016 and initiated March 11, 2016. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 7908 vials; Lot: Lot #: a) C500006, Exp 11/17; b) C500001, Exp 11/17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide and Puerto Rico
Lot
Lot #: a) C500006, Exp 11/17; b) C500001, Exp 11/17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ceftriaxone for Injection USP, 500 mg, Single Use Vial, packaged in a) 1-count Vials per box (NDC 68180-622-01), and b) 10-count Vials per box (NDC 68180-622-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., 111 South Calvert Street, Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Mandideep 462 046 INDIA. recalled?

Yes. FDA published recall D-0952-2016 on June 8, 2016. Reported hazard: CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail